3 New Strong Buy Ratings from Top-Rated Analysts: 04/28/2026

Make space on your watchlist: All of today’s picks have intense upside potential…

• TE Connectivity (NYSE: TEL) — Top analysts eye 25%+ upside after record Q2 beat
• Teva Pharmaceutical (NYSE: TEVA) — Unanimous Strong Buy with 45% upside and FDA catalysts ahead
• Neurocrine Biosciences (NASDAQ: NBIX) — Citi sees 89% upside on this biotech breakout

P.S. For more high-potential tickers, check out our latest video drop. 

A note from our sponsors...

1. TE Connectivity (NYSE: TEL)

TE Connectivity powers the world's transportation, industrial, and communications sectors with cutting-edge connectivity and sensor solutions across global markets. After delivering record-breaking Q2 earnings — crushing estimates with 15% sales growth and 20%+ EPS growth — top-tier analysts are circling, even as the stock trades at a discount.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $214.67 — get current quote

Max 1-year forecast: $297.00

Why we're watching:

• Analyst support: Wall Street maintains strong conviction with 7 Strong Buy ratings, 2 Buy ratings, and 4 Hold ratings among 13 analysts covering the stock. See the ratings
• For example, Goldman Sachs' Mark Delaney (a top 2% rated analyst) maintains a Strong Buy rating with a $270 price target, representing +25.77% upside potential.
• Oppenheimer's Christopher Glynn (a top 6% rated analyst) sees even more upside with a $285 price target, citing the company's strong commercial momentum and transformational progress.
• Industry ranking context: TEL is currently the 2nd highest-rated stock in the Electronic Components industry, which has an Industry Rating of A. (What’s #1? See the full list here.)
• Zen Rating highlights: TEL has an exceptional Zen Rating of A or Strong Buy, putting it in a class of stocks that have historically delivered 32.52% annual returns.
• Component Grades: TEL demonstrates exceptional Safety metrics with an A grade, balanced by strong B grades in Value, Growth, and Financials, positioning the stock as a defensive growth play in the electronic components sector. See all 7 Zen Component Grades here

2. Teva Pharmaceutical Industries (NYSE: TEVA)

Teva Pharmaceutical is a global powerhouse in generics, specialty medicines, and biopharmaceuticals. With a robust pipeline, sharpened cost discipline, and multiple FDA approvals on the horizon, this pharma giant is quietly setting the stage for sustained growth — even amid market turbulence.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $30.64 — get current quote

Max 1-year forecast: $45.00

Why we're watching:

• Analyst support: Overwhelming bullish sentiment with 6 Strong Buy ratings and 1 Buy rating from 7 analysts, representing unanimous positive coverage. See the ratings
• Bank of America's Jason Gerberry (a top 15% rated analyst) maintains a Strong Buy rating with a $42 price target, suggesting over 37% potential upside in the coming year, noting that Teva is well positioned for future growth with a positive outlook on new drug approvals and strong demand in the generics market.
• Industry ranking context: TEVA is currently the 3rd highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of A.
• Zen Rating highlights: TEVA ranks in the top 5% of stocks we track based on a 115-factor fundamental check, resulting in an overall A or Strong Buy rating. 
• Component Grades: TEVA shows balanced fundamentals with B grades across Value, Growth, Momentum, Safety, and AI, though Sentiment and Financials come in at C — suggesting an attractive but not flawless value play in pharmaceuticals. See all 7 Zen Component Grades here

3. Neurocrine Biosciences (NASDAQ: NBIX)

Neurocrine Biosciences is a leader in pharmaceuticals targeting neurological, endocrine, and psychiatric disorders, anchored by its blockbuster tardive dyskinesia franchise. Fresh two-year CRENESSITY data — showing sustained glucocorticoid dose reductions while maintaining androgen control in adults with classic congenital adrenal hyperplasia — is supercharging the bull case heading into Q1 earnings.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $127.68 — get current quote

Max 1-year forecast: $242.00

Why we're watching:

• Analyst support: Strong conviction from Wall Street with 9 Strong Buy ratings, 6 Buy ratings, and 3 Hold ratings among 18 analysts covering the stock. See the ratings
• Let’s look at a few of the ratings. For one, Needham's Ami Fadia (a top 1% rated analyst) reiterated a Buy rating with a $185 price target, representing +44.89% upside potential.
• Citigroup's Yigal Nochomovitz (a top 7% rated analyst) maintains the highest price target at $242, representing an impressive +89.54% upside potential.
• Industry ranking context: NBIX is currently the 7th highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of A. (See what ranks higher here.)
• Zen Rating highlights: TEVA earns an overall A or Strong Buy rating, indicating that it has a higher chance of outperformance than 95% of the stocks in our system.
• Component Grades: NBIX demonstrates outstanding fundamentals with top-tier A grades in both Value and Financials, supported by solid B grades in Growth and AI — positioning it as a high-quality, deeply undervalued pharmaceutical growth story, though investors should note softer Momentum, Sentiment, and Safety scores. See all 7 Zen Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.